WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation

Area of Science:

• Biochemistry
• Pharmacology
• Vascular Biology

Background:

• Plasminogen activator inhibitor-1 (PAI-1) is a primary inhibitor of tissue plasminogen activator (tPA).
• Elevated PAI-1 levels are associated with vascular remodeling diseases.
• There is a need for effective inhibitors of active PAI-1.

Purpose of the Study:

• To characterize a novel inhibitor of active PAI-1, WAY-140312.
• To evaluate the in vitro and in vivo efficacy of WAY-140312.
• To assess the safety profile of WAY-140312 concerning hemostasis.

Main Methods:

• Fluorescence spectroscopy was used to determine binding kinetics between WAY-140312 and PAI-1.
• Biochemical assays measured the inhibition of tPA activity by PAI-1 and the blocking effect of WAY-140312.
• In vivo studies in rats assessed the effect of oral WAY-140312 on plasma active PAI-1 levels.
• Hemostasis parameters including bleeding time, clotting time, and platelet aggregation were evaluated.

Main Results:

• WAY-140312 binds to PAI-1 with a dissociation constant of 5 µM.
• WAY-140312 effectively blocked PAI-1 inhibition of tPA activity with an IC(50) of 15.6 µM.
• An oral dose of 10 mg/kg WAY-140312 significantly reduced plasma active PAI-1 in rats.
• WAY-140312 did not affect bleeding time, thrombin clotting time, or platelet aggregation.

Conclusions:

• WAY-140312 is a potent, orally active inhibitor of PAI-1.
• This inhibitor demonstrates efficacy in reducing plasma active PAI-1 in vivo.
• WAY-140312 maintains normal hemostatic function, suggesting a favorable safety profile.